The purpose of current study is to test the feasibility and repeatability of MCC measurements made with the SILP method at 6 study sites. If successful, this will provide the groundwork needed to proceed with multi center therapeutic trials using this MCC assay.

To see if patients benefit from IV amino acids and exercise while in the ICU.

To collect research samples from CF patients already having a clinically indicated colonoscopy. We're collecting a few additional samples on top of what is collected for clinical purposes to give to researchers for future projects. This will increase your time of procedure around 5 minutes.

Patients will undergo a blood draw for a gene classifier test. Some patients will have their physicians informed of the result, and another group of patients will be randomized to be managed by standard of care. Qualifying patients have incidentally identified lung nodules assessed as < 50% risk of cancer.

To follow people with cystic fibrosis who have cultured a positive NTM bacteria.

The primary objective of PATIENCE is to develop a standardized approach to the treatment of NTM in CF patients with a diagnosis of NTM disease. The secondary objectives are to: - Evaluate the feasibility and tolerability of a standardized treatment protocol for NTM disease - Evaluate effectiveness of a standardized NTM disease treatment protocol to serve as baseline/reference estimates of endpoints in clinical care and future therapeutic trials - Support biomarker development for markers of NTM treatment response through banking of clinical specimens and NTM isolates linked with outcomes data - Characterize clinical features of patients achieving treatment success compared to those unresponsive to treatment

The virus that causes COVID-19 disease infects many people, but only some get sick. We want to understand how COVID affects the immune system and what makes severe COVID infections different from other diseases that cause hospitalization and breathing problems. We collect samples of blood, sputum, urine, and stool from patients in the hospital to learn how COVID affects cells and molecules of the immune system.

This study will test how effectively changes in lung structure and function can be detected with a new inhaled gas combined with a MRI.

To 1) measure and improve the quality of care, 2) determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understand risk factors for outcomes , and 4) facilitate funded clinical trials of new therapies and collaboration within the pulmonary arterial hypertension (PAH) community.

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progressive phenotype, HRCT images will be collected throughout the study for use in future research efforts.